Dr. Michelina Cairo, M.D.
What this data tells you about Dr. Cairo
Dr. Michelina Cairo is a medical oncology specialist in Houston, TX, with 15 years of NPI registration. Based on federal Medicare data, Dr. Cairo performed 40,764 Medicare services across 760 unique beneficiaries.
Between the years covered by Open Payments, Dr. Cairo received a total of $62,874 from 33 pharmaceutical and/or device companies across 134 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Cairo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 11,985 | $2 | $20 |
| Iron sucrose injection (Venofer) | 11,700 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 10,950 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 2,160 | $18 | $66 |
| Dexamethasone injection (steroid) | 1,125 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 980 | $1 | $114 |
| Complete blood count (CBC) with differential | 358 | $8 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 257 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 145 | $104 | $707 |
| Blood draw (venipuncture) | 135 | $8 | $20 |
| Drug injection, under skin or into muscle | 132 | $11 | $96 |
| Office visit, established patient (20-29 min) | 120 | $62 | $250 |
| Injection of additional new drug or substance into vein | 106 | $12 | $108 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 103 | $50 | $313 |
| Office visit, established patient (10-19 min) | 100 | $38 | $150 |
| Office visit, established patient (30-39 min) | 66 | $96 | $368 |
| Injection, diphenhydramine hcl, up to 50 mg | 65 | $1 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 61 | $27 | $145 |
| Administration of chemotherapy into vein, each additional hour | 61 | $22 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 38 | $52 | $344 |
| Irrigation of implanted venous access drug delivery device | 33 | $19 | $114 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 32 | $26 | $83 |
| New patient office visit, complex (60-74 min) | 27 | $178 | $709 |
| Office visit, established patient, complex (40-54 min) | 25 | $124 | $496 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (57%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Cairo is a mixed practice specialist, with above-average Medicare volume (top 23% in TX), with consulting-driven industry engagement in the top 20% of TX peers, with 15 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Cairo experienced with darbepoetin injection (aranesp) for anemia?
Does Dr. Cairo receive payments from pharmaceutical companies?
How do Dr. Cairo's costs compare to other medical oncologists in Houston?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology